Novel discoveries on aggressive NK-cell leukemia pave the way for new treatments

April 19, 2018, University of Helsinki

An international research consortium led by researchers from the University of Helsinki, Finland, has discovered new information related to a rare form of leukemia called aggressive NK-cell leukemia. Potential new treatment options were found which are highly warranted as currently this disease usually leads to rapid death of patients. The study was published in Nature Communications.

Aggressive NK-cell (ANKL) is a cancer in which consist of , a part of our immune system in normal conditions. The disease is very rare and aggressive: with the current (cytostatic drugs and hematopoietic stem cell transplantation) patients usually survive only a couple of months. This leukemia type is more common in the Asian population. However, related diseases such as NK/T-cell lymphomas occur also in western countries.

Together with Japanese, South-Korean, Taiwanese and US research teams, the researchers from the University of Helsinki aimed to discover which genetic defects are typical in this type of leukemia.

"ANKL patients often had mutations in the STAT3 and DDX3X genes which points towards partly shared genetic background with other NK- and T-cell malignancies," says Professor Satu Mustjoki, University of Helsinki, whose group initially discovered somatic STAT3 mutations in LGL leukemia.

By comparing the exome sequencing data from ANKL patients to previously published datasets from NK/T-cell lymphoma patients, researchers also uncovered novel gene amplifications in the JAK-STAT signaling pathway. In some cases, the amplified regions in the genome also included the PD-L1 gene which has therapeutic potential. In other lymphoma types, tumors with amplifications in the PD-L1 gene have responded well to novel immune checkpoint inhibitor therapies.

Researchers also aimed to discover novel potential drugs for the treatment of ANKL by testing the ability of over 400 different drugs to kill malignant and normal NK cells in cell culture conditions. Some potential drug candidates were discovered: NK were especially sensitive for drugs which inhibit JAK tyrosine kinases and anti-apoptotic BCL family members. JAK inhibitors inhibit the same signaling pathway in which genetic alterations were discovered in ANKL .

"JAK inhibitors, currently used in the treatment of rheumatoid arthritis and some other hematological diseases, could potentially improve the treatment of various NK-cell malignancies," says MD/Ph.D. student Olli Dufva who is the first author in the publication.

Explore further: Finnish researchers identify the cause for LGL leukemia

More information: Olli Dufva et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target, Nature Communications (2018). DOI: 10.1038/s41467-018-03987-2

Related Stories

Finnish researchers identify the cause for LGL leukemia

May 16, 2012
Researchers of the University of Helsinki, Helsinki University Central Hospital and Institute for Molecular Medicine Finland, have discovered that a mutation in the STAT3 gene is an underlying cause for LGL leukemia. Since ...

Study links mutations in notch gene to role in B cell cancers

October 23, 2017
Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States. It is also often mutated in other common B cell tumors, such as mantle cell ...

An epigenetic lesion could be responsible for acute T-cell leukemia

March 30, 2017
Researchers from the Epigenetics and Cancer Biology Program (PEBC) led by Dr. Manel Esteller at the Bellvitge Biomedical Research Institute (IDIBELL) have discovered how an epigenetic lesion can lead to T-cell acute lymphoblastic ...

The HLF-gene controls the generation of our long-term immune system

November 22, 2017
A research group at Lund University in Sweden has found that when the HLF (hepatic leukemia factor) gene –which is expressed in immature blood cells – does not shut down on time, we are unable to develop a functional ...

New drug cocktail unlocks potential of new leukemia treatment

January 23, 2017
A new combination of drugs, tested by University of Manchester scientists, has significantly enhanced the survival of laboratory mice with lymphoma.

New gene mutations found in white blood cells in patients with rheumatoid arthritis

June 21, 2017
Gene mutations accumulating in cells are typical of the development of cancer. Finnish researchers have found that a similar accumulation of mutations occurs also in some patients with rheumatoid arthritis.

Recommended for you

Scientists reveal likely cause of childhood leukaemia

May 21, 2018
A major new analysis reveals for the first time the likely cause of most cases of childhood leukaemia, following more than a century of controversy about its origins.

Compound in citrus oil could reduce dry mouth in head, neck cancer patients

May 21, 2018
A compound found in citrus oils could help alleviate dry mouth caused by radiation therapy in head and neck cancer patients, according to a new study by researchers at the Stanford University School of Medicine.

Ice cream funds research showing new strategy against thyroid cancer

May 21, 2018
Anaplastic thyroid cancer is almost uniformly fatal, with an average lifespan of about 5 months after diagnosis. And standard treatment for the condition includes 7 weeks of radiation, often along with chemotherapy.

Bladder cancer model could pave the way for better drug efficacy studies

May 21, 2018
Understanding that not all bladder cancers are the same, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have created a tool that may help them to uncover why only a fraction of patients ...

MR spectroscopy imaging reveals effects of targeted treatment of mutant IDH1 gliomas

May 18, 2018
Using a novel imaging method, a Massachusetts General Hospital (MGH) research team is investigating the mechanisms behind a potential targeted treatment for a subtype of the deadly brains tumors called gliomas. In their report ...

Particle shows promise to prevent the spread of triple-negative breast cancer

May 18, 2018
USC researchers have pinpointed a remedy to prevent the spread of triple-negative breast cancer. Metastatic breast cancer is a leading cause of death for women. The findings appear today in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.